Dapagliflozin enhances gut barrier function in rats with chronic myocardial infarction by modulating gut microbiota balance
Chanon Kunasol, Chayodom Maneechote, Nattayaporn Apaijai, Chanisa Thonusin, Chitlada Parbao, Wichwara Nawara, Nipon Chattipakorn, Siriporn C Chattipakorn · 2025
Read Dapagliflozin enhances gut barrier function in rats with chronic myocardial infarction by modulating gut microbiota balance by Chanon Kunasol, Chayodom Maneechote, Nattayaporn Apaijai, Chanisa Thonusin, Chitlada Parbao, Wichwara Nawara, Nipon Chattipakorn, Siriporn C Chattipakorn (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12771050.txt.
Description
Chanon Kunasol and co-authors present a 2025 rat study of a diabetes drug's effect on gut health after a heart attack. Lasting heart damage upsets the gut, which can feed back on the heart. Rats with heart damage got the drug or plain water for ten weeks.
Treated rats had better heart function. Their gut microbe mix regained variety, with more helpful species and fewer harmful ones. Gut wall proteins tightened, and gut cell death and swelling fell. A helpful short fat acid rose while a harmful blood marker fell. The authors say the gut changes may share in the heart benefit, but cause is not yet shown.
Catalog record
| CREATOR | Chanon Kunasol, Chayodom Maneechote, Nattayaporn Apaijai, Chanisa Thonusin, Chitlada Parbao, Wichwara Nawara, Nipon Chattipakorn, Siriporn C Chattipakorn |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |